摘要
我国已建立起一整套药品价格管制政策,但是,以成本加成为基础的价格管制与其他体制与机制性因素互动作用后,促成并强化了我国特定背景下医药不正当利益纽带关系。现行的成本加成定价管理是对企业创新产生的成本的补偿,而不是对企业创新产生的价值的回报。在成本加成的定价管理基础上,综合考虑药品的创新程度及其对医疗费用的影响,同时参考周边国家和地区同一药品品种的市场销售价格,可以作为我国药品价格管制变革的替代性方案。更长远地,我国应该构建以价值为基础的药品价格管制方式,以药品的成本效果为导向合理确定其相对价格水平。对仿制药可借鉴国际经验采用参考定价方法。
A set of pharmaceutical price regulation has been established in China. However, cost-plus pricing management, interacted with other institutional and mechanism factors, contributed to the formation of inappropriate interest relationship between medical services and pharmaceutical utilization. A mixed price regulation program based on cost-plus pricing management, combined with considering innovation degree of pharmaceutical products and their impact on medical expenditures as well as comparative price level in other neighboring countries and regions, is regarded as an alternative choice. In the long run, a value-based price regulation for pharmaceuticals is reeommended, which will be employed to determine comparative priee level of pharmaeeutical products based on cost effectiveness evaluation. As regards patent-eopied drugs, it is to suggest the reference pricing method borrowed from the internartional experiences.
出处
《中国卫生政策研究》
2008年第3期35-38,共4页
Chinese Journal of Health Policy
关键词
价格管制
可及性
成本加成定价
Price regulation, Accessibility, Cost-plus pricing
